Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2026 15:54 ET | Source: Hemex Health

Hemex Health Receives FDA Breakthrough Device Designation for Gazelle® Hb Variant Test

PORTLAND, Ore., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Hemex Health, a medical diagnostics company focused on decentralized testing for blood-based conditions, today announced that the U.S. Food and Drug...
February 05, 2026 09:26 ET | Source: Equity Insider

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad...
February 05, 2026 09:15 ET | Source: Longeveron

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Longeveron supports the passing of the Mikaela Naylon Give Kids a Chance Act which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program.
February 03, 2026 08:00 ET | Source: Byonyks

Byonyks X1: Revolutionizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.

Byonyks’ FDA-cleared X1 advances home dialysis innovation, with Farrukh Usman leading a mission to transform patient-centric renal care globally.
January 30, 2026 10:59 ET | Source: Elevar Therapeutics

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma

FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
January 30, 2026 07:00 ET | Source: Nutriband Inc.

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

Annual shareholder meeting highlights
January 29, 2026 10:46 ET | Source: Quetzal Therapeutics

QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia

CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S. Food and Drug Administration...
January 28, 2026 17:04 ET | Source: Elevar Therapeutics

Elevar Therapeutics Submits New Drug Application to FDA for Lirafugratinib as Second-Line Treatment Option for Cholangiocarcinoma

FORT LEE, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
January 28, 2026 12:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
January 28, 2026 07:40 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Successful Type C Meeting with the FDA

LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...